Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AXL inhibition improves BRAF-targeted treatment in melanoma
Marta Nyakas, Karianne G. Fleten, Mads H. Haugen, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
Zhenduo Shi, Kun Pang, Zhuo‐Xun Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 105
TAM family kinases as therapeutic targets at the interface of cancer and immunity
Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 755-779
Closed Access | Times Cited: 46
Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma
Shun Wang, Zhu Le, Tianen Li, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 2, pp. 101415-101415
Open Access | Times Cited: 30
AXL signaling in cancer: from molecular insights to targeted therapies
Monika Yadav, Anuj K. Sharma, Ketki Patne, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
Ferroptosis as a promising therapeutic strategy for melanoma
Na Ta, Xiaodong Jiang, Yongchun Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 19
Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer
Rui Han, Conghua Lu, Chen Hu, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 6, pp. 1264-1275
Closed Access | Times Cited: 8
Development of Personalized Strategies for Precisely Battling Malignant Melanoma
Armond J. Isaak, G Clements, Rand Gabriel M. Buenaventura, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 5023-5023
Open Access | Times Cited: 6
Advances in targeted therapy and immunotherapy for melanoma (Review)
Ziyao Qin, Mei Zheng
Experimental and Therapeutic Medicine (2023) Vol. 26, Iss. 3
Open Access | Times Cited: 16
Recent discovery and development of AXL inhibitors as antitumor agents
Z. Liu, Li Chen, Jifa Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116475-116475
Closed Access | Times Cited: 6
Molecular and therapeutic landscape of ferroptosis in skin diseases
Jiayuan Le, Yu Meng, Ying Wang, et al.
Chinese Medical Journal (2024) Vol. 137, Iss. 15, pp. 1777-1789
Open Access | Times Cited: 6
Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment
Naji Kharouf, Thomas W. Flanagan, Sofie-Yasmin Hassan, et al.
Cancers (2023) Vol. 15, Iss. 12, pp. 3147-3147
Open Access | Times Cited: 11
Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers
Bernhard Biersack, Lubna H. Tahtamouni, Michael Höpfner
Receptors (2024) Vol. 3, Iss. 1, pp. 58-106
Open Access | Times Cited: 4
Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers
Bernhard Biersack, Bianca Nitzsche, Michael Höpfner
Cancer Drug Resistance (2025)
Open Access
Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma
Magdalena Kuras, Lázaro Betancourt, Runyu Hong, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 832-832
Open Access
EGFR influences the resistance to targeted therapy in BRAF V600E melanomas by regulating the ferroptosis process
Yuexin Sun, Haoyue Yu, Ying Zhou, et al.
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Open Access
Loss of fatty acid-binding protein 7 promotes B16F10 melanoma metastasis
Tunyanat Wannakul, Hirofumi Miyazaki, Motoko Maekawa, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Simultaneous targeted and discovery-driven clinical proteotyping using hybrid-PRM/DIA
Sandra Goetze, Audrey van Drogen, Jonas B. Albinus, et al.
Clinical Proteomics (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective
Elisabetta Fratta, Giorgio Giurato, R. Guerrieri, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Metabolic insights into tumor lymph node metastasis in melanoma
Jiayi Huang, Zixu Gao, Jiangying Xuan, et al.
Cellular Oncology (2024)
Closed Access | Times Cited: 2
Harnessing the Potential of Non-Apoptotic Cell Death Processes in the Treatment of Drug-Resistant Melanoma
Linyinxue Dong, Ceeane Paul Dagoc Vargas, Xuechen Tian, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 10376-10376
Open Access | Times Cited: 5
CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects
Winston Hibler, Glenn Merlino, Yanlin Yu
Cells (2023) Vol. 12, Iss. 23, pp. 2750-2750
Open Access | Times Cited: 5
Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies
Rachel Goodman, Douglas B. Johnson
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 10, pp. 1428-1442
Closed Access | Times Cited: 7
Systematic analysis of the transcriptional landscape of melanoma reveals drug-target expression plasticity
Brad Balderson, Mitchell E. Fane, Tracey J. Harvey, et al.
Briefings in Functional Genomics (2024)
Open Access | Times Cited: 1
Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors
Elena Muraro, Barbara Montico, Benedict Lum, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Gas6/AXL Alleviates Hepatic Ischemia/Reperfusion Injury by Inhibiting Ferroptosis via the PI3K/AKT Pathway
Mengting Zhan, Liu Deng, Lei Yao, et al.
Transplantation (2024) Vol. 108, Iss. 11, pp. e357-e369
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top